SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-081562
Filing Date
2024-03-29
Accepted
2024-03-29 08:03:54
Documents
13
Period of Report
2024-03-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d800276d8k.htm   iXBRL 8-K 27538
  Complete submission text file 0001193125-24-081562.txt   147179

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA alrn-20240325.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE alrn-20240325_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alrn-20240325_pre.xml EX-101.PRE 10816
17 EXTRACTED XBRL INSTANCE DOCUMENT d800276d8k_htm.xml XML 3574
Mailing Address 738 MAIN STREET UNIT 398 WALTHAM MA 02451
Business Address 738 MAIN STREET UNIT 398 WALTHAM MA 02451 617-995-0900
AILERON THERAPEUTICS INC (Filer) CIK: 0001420565 (see all company filings)

IRS No.: 134196017 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 24802069
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)